ML385: Selective NRF2 Inhibitor for Cancer and Oxidative Stress Research

Executive Summary: ML385 (CAS 846557-71-9) is a potent and selective small molecule inhibitor of the transcription factor NRF2, with an IC50 of 1.9 μM in A549 cell-based assays (APExBIO ML385 product page). NRF2 acts as a master regulator of cellular antioxidant responses and is implicated in the development of therapeutic resistance in various cancers, especially non-small cell lung cancer (NSCLC) (Zhou et al., 2024). ML385 demonstrates dose- and time-dependent inhibition of NRF2-driven gene expression and reduces tumor growth and metastasis in NSCLC mouse xenograft models, particularly when combined with chemotherapeutics such as carboplatin. The compound is insoluble in ethanol and water but soluble to at least 13.33 mg/mL in DMSO under laboratory conditions. Researchers rely on ML385 to study NRF2-mediated signaling, oxidative stress modulation, and mechanisms of cancer therapeutic resistance in vitro and in vivo.

Biological Rationale

Nuclear factor erythroid 2-related factor 2 (NRF2) is a transcription factor central to the regulation of antioxidant response elements (AREs) and cellular defense mechanisms. Elevated NRF2 activity leads to increased expression of genes involved in detoxification, glutathione metabolism, and multidrug transporter expression, contributing to cancer cell survival and chemoresistance (Zhou et al., 2024). In non-small cell lung cancer (NSCLC), persistent NRF2 activation correlates with poor prognosis and therapeutic failure. Targeting NRF2 with selective inhibitors offers a promising strategy for sensitizing cancer cells to chemotherapy and for dissecting underlying oxidative stress signaling pathways. ML385, supplied by APExBIO, enables researchers to pharmacologically modulate NRF2, facilitating the study of oxidative stress, ferroptosis, and resistance mechanisms in cancer and liver disease models.

Mechanism of Action of ML385

ML385 is a non-electrophilic, small molecule inhibitor that selectively binds to the Neh1 DNA-binding domain of NRF2. By disrupting the interaction between NRF2 and AREs, ML385 prevents NRF2 from activating downstream target gene transcription. This leads to the downregulation of genes such as NQO1, GCLC, and HO-1 that are critical for cellular antioxidant defense. ML385 exhibits a half-maximal inhibitory concentration (IC50) of 1.9 μM in A549 NSCLC cells, confirming its potency in biological systems (APExBIO ML385 product page). Importantly, ML385 does not significantly inhibit related transcription factors or upstream regulators, confirming its selectivity for NRF2.

Evidence & Benchmarks

• ML385 (100 mg/kg/day, intraperitoneal) effectively blocks NRF2 activity in rodent models, leading to altered liver function and lipid profiles in alcoholic liver disease studies (Zhou et al., 2024).
• In vitro, ML385 reduces NRF2-dependent gene expression—including NQO1 and GCLC—at concentrations ≥1 μM in NSCLC cell lines (A549), with dose- and time-dependency (APExBIO ML385 product page).
• ML385 enhances the cytotoxicity of chemotherapeutic agents such as carboplatin in NSCLC mouse xenografts, resulting in reduced tumor growth and metastasis over 6 weeks (Zhou et al., 2024).
• ML385 is insoluble in water and ethanol but dissolves to ≥13.33 mg/mL in DMSO at room temperature, enabling use in both in vitro and in vivo protocols (APExBIO ML385 product page).
• Storage at –20°C maintains compound stability; long-term storage of solutions is not recommended due to risk of degradation (APExBIO ML385 product page).

This article extends prior guidance from ML385: Selective NRF2 Inhibitor for Cancer & Oxidative Stress by providing updated benchmarks and direct evidence from recent in vivo studies, clarifying the compound’s impact on ferroptosis and multidrug resistance.

Applications, Limits & Misconceptions

ML385 is primarily employed in cancer biology, toxicology, and redox signaling research. It supports studies on:

• Overcoming therapeutic resistance in NSCLC and other solid tumors by modulating NRF2 activity.
• Dissecting oxidative stress responses in models of liver injury, including alcoholic liver disease and ferroptosis-related pathologies.
• Combination therapy research, especially with platinum-based chemotherapeutics such as carboplatin.
• Functional genomics and pathway analysis of NRF2-regulated networks.

Common Pitfalls or Misconceptions

• ML385 is not a pan-antioxidant inhibitor: It selectively targets NRF2 and does not block all antioxidant pathways.
• Solubility constraints: ML385 is ineffective in aqueous or ethanol-based buffers; DMSO is required for stock solutions.
• Not suitable for chronic dosing: Long-term solution storage leads to compound degradation and unreliable results.
• Cell line specificity: Sensitivity to ML385 may vary; A549 NSCLC cells are well-validated, but responses in other lines require empirical optimization.
• NRF2-independent effects are minimal: Off-target activity is low, but always validate NRF2 dependency with genetic controls.

This article updates and expands upon ML385: Selective NRF2 Inhibition for Overcoming Cancer Resistance by emphasizing solubility and practical workflow integration.

Workflow Integration & Parameters

ML385 is supplied as a solid and should be dissolved in DMSO to ≥13.33 mg/mL for stock preparation. Recommended working concentrations for cell-based assays are 0.5–5 μM. In vivo, dosing regimens use 100 mg/kg/day administered intraperitoneally in rodent models (Zhou et al., 2024). Store the solid at –20°C and use freshly prepared solutions for each experiment to preserve activity. Validate NRF2 inhibition by quantifying expression of target genes (e.g., NQO1, HO-1) and confirm pathway specificity using genetic knockdown where possible. For a comprehensive stepwise protocol, see ML385 (SKU B8300): Reliable NRF2 Inhibition for Advanced Research, which this article complements by providing updated in vivo performance metrics and solubility guidelines.

Conclusion & Outlook

ML385, provided by APExBIO, is a reference-standard tool in NRF2 pathway inhibition, enabling detailed studies of oxidative stress, cancer resistance, and combination therapies. Its potency, selectivity, and reproducible benchmarks make it indispensable for investigating NRF2 function in diverse disease models. As NRF2-targeted interventions advance toward clinical translation, ML385 remains a critical reagent for mechanistic studies and therapeutic evaluation in preclinical research. Researchers are advised to consult the ML385 B8300 kit page for the latest specifications and validated applications.